Investing to benefit people and the planet

2022 results CEO video

Our 2022 results are released. Watch the video to hear our CEO Kasim Kutay’s reflections on a year when Novo Holdings, despite a challenging backdrop, reported positive Total Income and Returns, driven by a strong performance from Novo Nordisk and Novozymes, as well as a strong relative performance by the Investment Portfolio.

Holdings and investments

Novo Holdings is a holding and investment company that is responsible for managing the assets and wealth of the Novo Nordisk Foundation, one of the world’s largest enterprise foundations.

Novo Holdings is the controlling shareholder of Novo Nordisk and Novozymes and manages an investment portfolio, with a long-term return perspective. In addition to managing a broad portfolio of equities, bonds, real estate, infrastructure and private equity assets, Novo Holdings is a world-leading life science investor. Through its Seeds, Venture, Growth and Principal Investments teams, Novo Holdings invests in life science companies at all stages of development.

As of year-end 2022, Novo Holdings had total assets of EUR 108 billion. For more information, download our fact sheet.

Our people embrace a culture of high performance with respect and responsibility

Our collegues aspire to be leading responsible investors, recognised for delivering strong financial returns and positive societal impact.

Meet us

Our people embrace a culture of high performance with respect and responsibility

Our collegues aspire to be leading responsible investors, recognised for delivering strong financial returns and positive societal impact.

Meet us

Our guiding principles

Values Driven

A values-based company:

We strive for high performance
with respect and responsibility

Leading by example

Ambitious Strategy

Return Driven

Life Science Allocation

Significant Direct Investments

Capital Investments Pillar

Operational Excellence

Ensuring solid foundations for success

Talent Nurture & Development

Governance & Processes

Strong collaboration and cohesion

To be a leading responsible investor, recognized for delivering strong financial returns and positive societal impact

To be a leading responsible investor, recognized for delivering strong financial returns and positive societal impact

Responsible Investments at Novo Holdings

We aspire to become catalysts of change by investing in companies that – like Novo Holdings – believe that we have a responsibility to alleviate the pressing challenges facing humankind and our planet. Read more.

Responsible Investments at Novo Holdings

We aspire to become catalysts of change by investing in companies that – like Novo Holdings – believe that we have a responsibility to alleviate the pressing challenges facing humankind and our planet. Read more.

Annual review

  • 108 bn

    Total investment assets of Novo Holdings at the end of 2022

  • 7 %

    Total 5-year return on the Investment Portfolio

  • 11 %

    10-year trailing returns on the Investment Portfolio

Novo Holdings A/S
Tuborg Havnevej 19
2900 Hellerup
Denmark
+45 3527 6500
CVR# 24257630

Novo Ventures (US) Inc.*
200 Clarendon Street, Floor 45
Boston, MA 02116
USA

Novo Ventures (US) Inc.*
One Market St., Steuart Tower, 17th Floor
San Francisco, CA 94105
USA
+1 (415) 552-6686

Novo Holdings Equity Asia Pte. Ltd.*
6 Battery Road #23-03
Singapore 049909
Singapore

Novo Holdings Equity US Inc.*
One Market St., Steuart Tower, 17th Floor
San Francisco, CA 94105
USA
+1 (415) 552-6686

Novo Holdings Equity US Inc.*
200 Clarendon Street, Floor 45
Boston, MA 02116
USA

Novo Holdings (UK office)
16 Berkeley Street, Mayfair
London W1J 8DZ
UK

Media Relations
Christian Mostrup Scheel
Senior Press Officer
cims@novo.dk
+45 3067 4805

*Novo Ventures (US) Inc., Novo Holdings Equity US Inc., comprising Novo Growth and Principal Investments, and Novo Holdings Equity Asia Pte. Ltd. are separate legal entities that provide certain consultancy services to Novo Holdings A/S, mainly within the areas of identifying, analysing and negotiating various investment opportunities among life science and biotech companies in the US as well as certain follow-up activities related thereto, such as board memberships, financial control and reporting efforts.